Small clinical cohorts are a reality in translational oncology, making reliable model validation essential. Our ESMO AI 2026 poster examines how cross-validation design affects reported biomarker performance and what this means for evaluating predictions when clinical data are limited.

Published for ESMO AI 2026.

Authors:
Miha Štajdohar, Gregor Jerše

Genialis, Inc., Boston, MA, USA

Share this story, choose your platform!